Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
Recruiting · Phase 3 · NCT05722938
Conditions: Community-acquired Pneumonia
At a glance
- Research payments reported, 2025
- $270,218
- U.S. investigators named
- 5
- Sites paid
- 5
- Planned or actual enrollment
- 590
About the trial
- Sponsor
- Biotest
- Tested
- Trimodulin (drug), Placebo (human albumin 1%) (drug)
- Dates
- Started 2023-09-09; completion 2028-07-31
- Results posted
- Not yet
The main objective of the trial is to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in hospitalized subjects with sCAP on invasive mechanical ventilation (IMV). Other objectives are to determine detailed pharmacokinetic (PK) properties of trimodulin in a PK substudy and to determine its pharmacodynamic (PD) properties.
From ClinicalTrials.gov, last updated 2026-09-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Biotest AG reported $270,218 in research payments for this study in 2025 (5 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Timothy E. Albertson, MD, PHD, MPH Critical Care Medicine · Sacramento, CA
- Eyad Almasri, M.D. Pulmonology · Fresno, CA
- Mohammed M. Alnijoumi, M.D. Pulmonology · Detroit, MI
- Todd Rice, MD Critical Care Medicine · Nashville, TN
- Estelle S. Harris, MD Critical Care Medicine · Salt Lake City, UT
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.